TELA TELA Bio

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference.

TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at .

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit .

Investor Contact

Louisa Smith



EN
19/11/2025

Underlying

TELATELA Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TELA Bio

 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Co...

TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 37th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at . About TELA Bio, In...

4h / 36m 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
WEX WEX INC.
TPVG TRIPLEPOINT VEN... ... (+34)

InsiderInsights.com Daily Ratings Report: November 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WEX WEX INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
11/18/25 November 18, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a gra...

November 17, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Di...

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of $1.11 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 7,523,000 shares of common stock at an offering p...

November 13, 2025 1 EN
 PRESS RELEASE
Free
TELA TELA BIO

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing ...

TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highli...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch